ImmunityBio (IBRX) Operating Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Operating Expenses data on file, last reported at $114.0 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $114.0 million, up 40.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $402.4 million (up 16.75% YoY), and the FY2025 annual result was $369.3 million, up 2.89% from the prior year.
• Operating Expenses climbed to $114.0 million in Q1 2026 per IBRX's latest filing, from $103.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $114.0 million in Q1 2026 and troughed at $77.0 million in Q4 2024.
• A 5-year average of $91.6 million and a median of $87.7 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses decreased 15.0% in 2025, then surged 40.83% in 2026.
• A 5-year view of Operating Expenses shows it stood at $85.0 million in 2022, then advanced by 0.65% to $85.5 million in 2023, then declined by 10.03% to $77.0 million in 2024, then surged by 33.81% to $103.0 million in 2025, then grew by 10.71% to $114.0 million in 2026.
• Business Quant data shows IBRX's Operating Expenses at $114.0 million in Q1 2026, $103.0 million in Q4 2025, and $87.7 million in Q3 2025.